Australia set to host clinical trial of genetically modified Covid nasal spray vaccine
Australian company applies for permission to conduct trial of men and women aged 18 to 55Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.Avance Clinical, an Australian contract research organisation, hasapplied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Paul Karp Tags: Vaccines and immunisation Coronavirus Australia news Science Health Source Type: news
More News: Adenoviruses | Australia Health | Clinical Trials | Contracts | Coronavirus | COVID-19 | Genetics | Science | Vaccines | Women